Protagonist Therapeutics, Inc. (PTGX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Newark, CA, United States. El CEO actual es Dinesh V. Patel.
PTGX tiene fecha de IPO 2016-08-11, 124 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $6.73B.
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's clinical pipeline includes rusfertide (PTG-300), an injectable hepcidin mimetic in Phase II trials for polycythemia vera and hereditary hemochromatosis; PN-943, an oral integrin antagonist peptide in Phase II development for inflammatory bowel disease; and PN-235, an orally delivered interleukin-23 receptor antagonist for IBD and other indications. Protagonist maintains a license and collaboration agreement with Janssen Biotech, Inc. and operates from its headquarters in Newark, California.
